Dogwood Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DWTX Nasdaq 2836 dwtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dogwood Therapeutics, Inc.

DWTX: Financing Secures Funding Through Phase 2b Data Readout - Feb 2nd, 2026 7:12 am
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - Feb 2nd, 2026 6:30 am
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - Jan 12th, 2026 6:30 am
DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15 - Dec 30th, 2025 4:15 am
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron - Dec 22nd, 2025 9:00 am
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain - Dec 22nd, 2025 8:15 am
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 - Dec 2nd, 2025 6:00 am
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 - Nov 11th, 2025 6:45 am
DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25… - Nov 10th, 2025 5:17 am
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results - Nov 6th, 2025 6:45 am
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Oct 30th, 2025 7:15 am
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 - Oct 14th, 2025 6:45 am
DWTX: Licenses SP16 for Treatment of Cancer Related Pain… - Oct 10th, 2025 6:04 am
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit - Oct 7th, 2025 6:45 am
Potential Government Shutdown in Focus as US Equity Futures Rise Pre-Bell - Sep 29th, 2025 7:08 am
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients - Sep 29th, 2025 5:15 am
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 7:15 am
DWTX: Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25 - Aug 20th, 2025 7:15 am
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results - Aug 13th, 2025 7:00 am
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial - Aug 7th, 2025 11:08 am